Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women

NCT01235754 is registered in ClinicalTrials.gov with BioSante Pharmaceuticals as lead sponsor.

NCT NCT01235754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women
Lead sponsor
BioSante Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
January 31, 2012
Enrollment
626 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

hypoactive sexual desire disorder